Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
failed trials
Biotech
MoonLake stock sinks as high placebo rate eclipses ph. 3 results
MoonLake blamed an unexpectedly high placebo response rate for its much-hyped inflammatory disease prospect missing the key goal of a phase 3 study.
James Waldron
Sep 29, 2025 8:05am
Enanta sees RSV drug fail phase 2b but finds positives
Sep 29, 2025 8:05am
Harmony's pivotal trial flops as placebo response causes discord
Sep 24, 2025 9:35am
Sanofi's R&D chief 'pretty pragmatic' about clinical setbacks
Sep 17, 2025 8:01am
aTyr flunks phase 3 lung disease trial, deflating stock
Sep 15, 2025 9:56am
Roche sees Alnylam RNAi drug flunk trial, still plans phase 3
Sep 1, 2025 4:39am
